Pazopanib is a multi-kinase inhibitor that inhibits the VEGF receptors VEGFR1, VEGFR2, and VEGFR3 (IC50s = 10, 30, and 47 nM, respectively, in a cell-free enzyme assay). It also inhibits PDGFRalpha, PDGFRbeta, and c-Kit (IC50s = 71, 84, and 74 nM, respectively, in a cell-free enzyme assay) as well as additional...

Pazopanib is an oral, second-generation, potent and selective multi-targeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor and c-kit, key proteins responsible for tumor growth and angiogenesis. Pazopanib showed good potency...

White to off-white solid. Soluble in DMSO (10mg/ml). Insoluble in water. Chemical. CAS: 444731-52-6. Formula: C21H23N7O2S. MW: 437.5. Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor. It is an orally available angiogenesis inhibitor targeting vascular endothelial growth factor...

Description: Pazopanib (GW786034) is an inhibitor of protein tyrosine kinases that inhibits VEGFR1, VEGFR2, VEGFR3, PDGFRbeta, c-Kit, FGFR1, and c-Fms (IC50=10/30/47/84/74/140/146 nM). Pazopanib has antitumor activity. Target: VEGFR, FGFR, c-Kit, PDGFR, Autophagy. Smiles:...